

TNF-alpha (Tumor Necrosis Factor alpha) Antibody - With BSA and Azide

Mouse Monoclonal Antibody [Clone J1D9]

Catalog # AH12433

Product Information

Application	IF, FC
Primary Accession	P01375
Other Accession	7124 , 241570
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Isotype	Mouse / IgG1, kappa
Clone Names	J1D9
Calculated MW	25644

Additional Information

Gene ID	7124
Other Names	Tumor necrosis factor, Cachectin, TNF-alpha, Tumor necrosis factor ligand superfamily member 2, TNF-a, Tumor necrosis factor, membrane form, N-terminal fragment, NTF, Intracellular domain 1, ICD1, Intracellular domain 2, ICD2, C-domain 1, C-domain 2, Tumor necrosis factor, soluble form, TNF, TNFA, TNFSF2
Application Note	IF~~1:50~200 FC~~1:10~50
Storage	Store at 2 to 8°C.Antibody is stable for 24 months.
Precautions	TNF-alpha (Tumor Necrosis Factor alpha) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	TNF
Synonyms	TNFA, TNFSF2
Function	Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T- cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the

expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:[23396208](#)). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:[16829952](#), PubMed:[22517918](#), PubMed:[23396208](#)). Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity). Plays a role in angiogenesis by inducing VEGF production synergistically with IL1B and IL6 (PubMed:[12794819](#)). Promotes osteoclastogenesis and therefore mediates bone resorption (By similarity).

Cellular Location

Cell membrane; Single-pass type II membrane protein [Tumor necrosis factor, soluble form]; Secreted [C-domain 2]; Secreted.

Background

This antibody neutralizes TNF alpha biological activities. It prevents TNF alpha induced apoptosis in Jurkat cells. It also neutralizes HurTNF mediated cytotoxicity of L929 cells and inhibits tumor growth in mice. It protects mice against toxicity of HurTNFa. Tumor Necrosis Factor Alpha (TNF alpha) is a protein secreted by lipopolysaccharide-stimulated macrophages, and causes tumor necrosis when injected into tumor bearing mice. TNF alpha is believed to mediate pathogenic shock and tissue injury associated with endotoxemia. TNF alpha exists as a multimer of two, three, or five non-covalently linked units, but shows a single 17kDa band following SDS PAGE under non-reducing conditions. TNF alpha is closely related to the 25kDa protein Tumor Necrosis Factor beta (lymphotoxin), sharing the same receptors and cellular actions. TNF alpha causes cytolysis of certain transformed cells, being synergistic with interferon gamma in its cytotoxicity. Although it has little effect on many cultured normal human cells, TNF alpha appears to be directly toxic to vascular endothelial cells. Other actions of TNF alpha include stimulating growth of human fibroblasts and other cell lines, activating polymorphonuclear neutrophils and osteoclasts, and induction of interleukin 1, prostaglandin E2 and collagenase production.

References

McLaughlin PJ; Elwood NJ; Russell SM; Andrew SM; McKenzie IF. Properties of monoclonal antibodies to human tumor necrosis factor alpha (TNF alpha). *Anticancer Research*, 1992, 12(4):1243-6. | P. Vassalli, *Annu Rev Immunol* 10: 411-452 (1992). | M. Paparakis, et al, *Cytokine and Growth Factor Reviews* 7: 223-229 (1996). | A. Eigler, et al, *Immunology Today* 18: 487-492 (1997). | Kalli K R, Kaufmann S H, et al. *Molecular Pharmacology* 64(6): 1434-1443 (2003). | R. Pijnenborg, et al, *Placenta* 19(4): 231-239 (1998)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.